SIMULATION MODEL OF IBRUTINIB IN TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)

被引：3
|
作者：
Peng, S. [1 ]
Sorensen, S. [1 ]
Pan, F. [1 ]
Dorman, E. [1 ]
Sun, S. [2 ]
Van Sanden, S. [3 ]
Sengupta, N. [4 ]
Gaudig, M. [5 ]
机构：
[1] Evidera, Bethesda, MD USA
[2] Janssen, Raritan, NJ USA
[3] Univ Hosp Leuven, Leuven, Belgium
[4] Janssen Pharmaceut Inc, Raritan, NJ USA
[5] Janssen Pharmaceut Inc, Neuss, Germany
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2196
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN38
引用
收藏
页码：A620 / A620
页数：1
相关论文
共 50 条
  • [41] A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma
    Martin, Peter
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ferrante, Lucille
    Londhe, Anil
    McGowan, Tracy
    Bartlett, Nancy L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (04) : 1027 - 1030
  • [42] REAL-WORLD TREATMENT OUTCOMES AMONG RELAPSED/REFRACTORY PATIENTS WITH MANTLE CELL LYMPHOMA TREATED WITH IBRUTINIB OR ACALABRUTINIB
    Crawford, S.
    Lafeuille, M. H.
    Emond, B.
    Harb, D.
    Voladarsky, R.
    Chen, N.
    Karve, S.
    VALUE IN HEALTH, 2023, 26 (06) : S403 - S403
  • [43] Temsirolimus In Relapsed and/or Refractory Mantle Cell Lymphoma
    Hoy, Sheridan M.
    McKeage, Kate
    DRUGS, 2010, 70 (14) : 1819 - 1829
  • [44] Management of relapsed/refractory mantle cell lymphoma
    Alzahrani, Musa
    Villa, Diego
    LEUKEMIA & LYMPHOMA, 2024, 65 (08) : 1044 - 1054
  • [45] TemsirolimusIn Relapsed and/or Refractory Mantle Cell Lymphoma
    Sheridan M. Hoy
    Kate McKeage
    Drugs, 2010, 70 : 1819 - 1829
  • [46] Dismantling relapsed/refractory mantle cell lymphoma
    Ryan, Christine E.
    Kumar, Anita
    BLOOD REVIEWS, 2024, 67
  • [47] Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
    Shah, Bijal
    Challagulla, Swetha
    Xu, Sheng
    Williams, Rhys
    Ren, Shijie
    Srivastava, Tushar
    Gautam, Raju
    Yang, Keri
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S516 - S517
  • [48] Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review
    Al-Mansour, Mubarak
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (11): : E1019 - E1031
  • [49] A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma
    Kim, Myung Sun
    Banerjee, Titas
    Chen, Andy
    Danilov, Alexey
    MacKinnon, Renee
    Thurlow, Bria
    Thakurta, Sujata
    Orand, Kirsten
    Degnin, Catherine
    Park, Byung
    Spurgeon, Stephen E.
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 722 - 724
  • [50] Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma
    Mussetti, Alberto
    Kumar, Anita
    Dahi, Parastoo B.
    Perales, Miguel-Angel
    Sauter, Craig S.
    BLOOD REVIEWS, 2015, 29 (03) : 143 - 152
12345